2016
Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival
Bordia R, Zhong H, Lee J, Weiss S, Han SW, Osman I, Jain R. Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival. Journal Of Neuro-Oncology 2016, 131: 341-348. PMID: 27822597, DOI: 10.1007/s11060-016-2305-8.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBrain NeoplasmsHumansKaplan-Meier EstimateMagnetic Resonance ImagingMelanomaProto-Oncogene Proteins B-rafRetrospective StudiesConceptsMelanoma brain metastasesSignificant prognostic factorsBRAF inhibitor treatmentPercent of lesionsBrain metastasesMedian survivalPrognostic factorsPatient survivalMultiple lesionsInhibitor treatmentT1-weighted hyperintensityBRAF mutation statusT1-weighted hyperintense signalsNumber of lesionsMethods PatientsRetrospective reviewInstitutional databaseLonger survivalHyperintense signalBrain MRIMelanoma metastasesSingle lesionEnhancement patternLarge lesionsLesion size
2015
Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis
Weiss S, Darvishian F, Tadepalli J, Shapiro R, Golfinos J, Pavlick A, Polsky D, Kirchhoff T, Osman I. Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer 2015, 15: 926. PMID: 26597176, PMCID: PMC4657192, DOI: 10.1186/s12885-015-1927-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrain NeoplasmsGerm-Line MutationGTP PhosphohydrolasesHumansMaleMelanomaMembrane ProteinsPrognosisProto-Oncogene Proteins B-rafSurvivorsTelomeraseConceptsMelanoma brain metastasesRecurrent brain metastasesBrain metastasesOverall survivalLong-term melanoma survivorsSingle nucleotide polymorphismsYear old manIndividual patient's tumorGenetic variantsMelanoma patientsMelanoma survivorsPrognostic informationFavorable outcomeNRAS wild typePatient outcomesConclusionsOur dataPatient tumorsImmune functionBrain tumorsExtended survivalOlder menPatientsClinical scenariosGermline analysisTherapeutic interventionsSensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression
Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D. Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression. Molecular Oncology 2015, 10: 157-165. PMID: 26440707, PMCID: PMC4695284, DOI: 10.1016/j.molonc.2015.09.005.Peer-Reviewed Original ResearchConceptsNew brain metastasesDisease progressionTreatment initiationBrain metastasesDisease activityCtDNA levelsMetastatic melanomaProgression eventsRECIST scoresUseful blood-based biomarkerImmune checkpoint blockadeDisease progression eventsBRAF inhibitor therapyBlood-based biomarkersCell-free DNA assaysCheckpoint blockadeMetastatic diseaseInhibitor therapyTreatment courseLDH levelsPatient managementUseful biomarkerPatientsDroplet digital PCR assaysProgression